Abstract
Plasmodium falciparum multidrug resistance-1 gene (pfmdr1) polymorphisms associate with altered antimalarial susceptibility. Between 2010 and 2018/2019, we observed that the prevalence of the wild-type allele N86 and the wild-type combination NYD increased 10-fold (4% versus 40%) and more than 2-fold (18% versus 44%), respectively. Haplotypes other than NYD or NFD declined by up to >90%. Our molecular data suggest the pfmdr1 pattern shifted toward one associated with artemether-lumefantrine resistance.
Keywords:
Plasmodium falciparum; Rwanda; malaria; multidrug resistance.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antimalarials* / pharmacology
-
Antimalarials* / therapeutic use
-
Artemether / therapeutic use
-
Artemether, Lumefantrine Drug Combination
-
Artemisinins* / pharmacology
-
Artemisinins* / therapeutic use
-
Drug Resistance / genetics
-
Humans
-
Malaria, Falciparum* / drug therapy
-
Multidrug Resistance-Associated Proteins* / genetics
-
Plasmodium falciparum / genetics
-
Polymorphism, Genetic / genetics
-
Rwanda
Substances
-
Antimalarials
-
Artemether, Lumefantrine Drug Combination
-
Artemisinins
-
Mdr1 protein, Plasmodium falciparum
-
Multidrug Resistance-Associated Proteins
-
Artemether